Ignite Creation Date:
2025-12-24 @ 6:41 PM
Ignite Modification Date:
2026-01-05 @ 5:18 PM
Study NCT ID:
NCT05480657
Status:
WITHDRAWN
Last Update Posted:
2023-01-18
First Post:
2022-07-27
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Safety, Tolerability, and Efficacy of Immunomodulation With AT-1501 in Combination With Transplanted Islet Cells in Adults With Brittle T1D
Sponsor:
Eledon Pharmaceuticals
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Brittle Type 1 Diabetes Mellitus | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | AT-1501 | View |
| None | Type 1 Diabetes | View |
| None | T1D | View |
| None | Islet Cell Transplant | View |
| None | humanized blocking antibody to CD40L | View |
| None | CD40L inhibitor | View |
| None | monoclonal antibody | View |
| None | Glucose Metabolism Diseases | View |
| None | Diabetes Mellitus | View |
| None | Type 1 | View |
| None | Endocrine System Diseases | View |
| None | Graft | View |
| None | Metabolic Diseases | View |
| None | Immune System Diseases | View |
| None | Autoimmune Diseases | View |
| None | Hypoglycemia | View |
| None | Hyperglycemia | View |
| None | Brittle T1D | View |
| None | Brittle Type 1 Diabetes | View |